Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PM 359

Next Previous
X
Search
Drug Profile

PM 359

Alternative Names: PM-359

Latest Information Update: 18 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prime Medicine
  • Class Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; Neutrophil cytosolic factor 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic granulomatous disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Chronic granulomatous disease

Most Recent Events

  • 26 Sep 2024 Phase-I/II clinical trials in Chronic granulomatous disease (In adolescents, In children, In the elderly, Treatment-experienced, In adults) in USA (IV) (NCT06559176),
  • 26 Sep 2024 Phase-I/II clinical trials in Chronic granulomatous disease (In adults, In children, In adolescents, In the elderly, Treatment-experienced) in Canada (IV) (NCT06559176)
  • 19 Aug 2024 Prime Medicine plans a phase I/II trial for Chronic granulomatous disease (Treatment experienced) in September 2024 (IV)(NCT06559176)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top